NCT05708404

Brief Summary

Approximately 20-30 % of individuals with the eating disorder anorexia nervosa develop an enduring form of the illness. In this study a new treatment for patients with severe and enduring anorexia nervosa was described. The treatment is flexible and aims at enhancing quality of life. The participants consisted of all referrals resulting in an assessment or treatment period at the unit between May 2017 and May 2022. The study was a registry study. Information regarding patient characteristics, treatment goals, and the course of treatment was gathered from medical records.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2017

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2017

Completed
5.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2022

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

January 11, 2023

Completed
21 days until next milestone

First Posted

Study publicly available on registry

February 1, 2023

Completed
Last Updated

February 1, 2023

Status Verified

January 1, 2023

Enrollment Period

5.1 years

First QC Date

January 11, 2023

Last Update Submit

January 23, 2023

Conditions

Keywords

Anorexia nervosaSevere and enduring anorexia nervosaTreatment

Outcome Measures

Primary Outcomes (1)

  • How the treatment goals were met

    Whether or not the patients' individual treatment goals, defined at the beginning of treatment, had been met, partly met, or not met at the end of treatment.

    At the end of treatment, an average of 15.4 months

Interventions

A novel outpatient treatment of severe and enduring anorexia nervosa, aiming at enhancing quality of life and minimizing harm

Eligibility Criteria

Age18 Years+
Sexfemale
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult women with severe and enduring anorexia nervosa.

You may qualify if:

  • Age ≥ 18 years
  • A referral resulting in an assessment or treatment period at the unit for patients with severe and enduring anorexia nervosa at the HUS Helsinki University Hospital between May 2017 and May 2022.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

HUS Syömishäiriöyksikkö

Helsinki, PL 282, 00029 HUS, Finland

Location

Related Publications (1)

  • Algars M, Oshukova S, Suokas J. A novel outpatient treatment model for patients with severe and enduring anorexia nervosa: an observational study of patient characteristics, treatment goals, and treatment course. J Eat Disord. 2023 Sep 6;11(1):150. doi: 10.1186/s40337-023-00877-x.

MeSH Terms

Conditions

AnorexiaAnorexia Nervosa

Condition Hierarchy (Ancestors)

Signs and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and SymptomsFeeding and Eating DisordersMental Disorders

Study Officials

  • Jaana Suokas, Ph.D.

    HUS Helsinki Central Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ph.D.

Study Record Dates

First Submitted

January 11, 2023

First Posted

February 1, 2023

Study Start

May 1, 2017

Primary Completion

May 31, 2022

Study Completion

May 31, 2022

Last Updated

February 1, 2023

Record last verified: 2023-01

Data Sharing

IPD Sharing
Will not share

Locations